Quintiles Contributes Open Source Code to ResearchKit
Available in GitHub, Code Brings New Tools to Research Studies
RESEARCH TRIANGLE PARK, N.C. – November 9, 2015 – Quintiles, the world’s largest biopharma services provider, has announced its contribution of enhancements to the ResearchKit framework which was designed by Apple to make it easy for researchers to gather data more frequently and more accurately from research participants using iPhone apps.
ResearchKit enables participants to easily complete tasks or submit surveys right from an app and delivers a simple way to present participants with an interactive informed consent process. Quintiles contributed enhancements to the ResearchKit framework to provide developers with extensions that support additional capabilities which, in turn, will allow them to create more sophisticated application experiences. Quintiles plans to use these enhancements to develop patient engagement tools for ResearchKit-based apps.
As the number one ranked late-phase research organization, Quintiles’ technology and digital health experts are actively integrating and further enhancing ResearchKit as a tool for its customers' research studies to deliver a superior patient and caregiver experience.
“Quintiles has a deep understanding of patient behavior, having conducted more than 400 direct-to-patient programs since 2008,” said Quintiles President of Technology and Solutions Richard Thomas. “We embraced those principles in our development of enhancements to the ResearchKit framework.”
“We believe Quintiles’ contribution of these enhancements is a significant advancement within the clinical research industry,” Thomas continued. “They will not only improve the apps Quintiles develops for its own use, but can enhance all apps developed using ResearchKit. Working with the ResearchKit framework gives us a profound understanding of its capabilities and how best to optimize it in the apps we develop for our clinical research customers.”
For more information on Quintiles’ contributions to ResearchKit, please visit our website at http://www.quintiles.com/researchapps.
About Quintiles
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
